RU2010144511A - АПОПТОТИЧЕСКАЯ ЧУВСТВИТЕЛЬНОСТЬ К Apo2L/TRAIL ПУТЕМ ТЕСТИРОВАНИЯ ЭКСПРЕССИИ GalNac-N14 В КЛЕТКАХ/ТКАНЯХ - Google Patents

АПОПТОТИЧЕСКАЯ ЧУВСТВИТЕЛЬНОСТЬ К Apo2L/TRAIL ПУТЕМ ТЕСТИРОВАНИЯ ЭКСПРЕССИИ GalNac-N14 В КЛЕТКАХ/ТКАНЯХ Download PDF

Info

Publication number
RU2010144511A
RU2010144511A RU2010144511/15A RU2010144511A RU2010144511A RU 2010144511 A RU2010144511 A RU 2010144511A RU 2010144511/15 A RU2010144511/15 A RU 2010144511/15A RU 2010144511 A RU2010144511 A RU 2010144511A RU 2010144511 A RU2010144511 A RU 2010144511A
Authority
RU
Russia
Prior art keywords
tissue
expression
galnac
cells
sample
Prior art date
Application number
RU2010144511/15A
Other languages
English (en)
Inventor
Клаус В. ВАГНЕР (US)
Клаус В. ВАГНЕР
Ави Дж. АШКЕНАЗИ (US)
Ави Дж. АШКЕНАЗИ
Original Assignee
Дженентек, Инк. (Us)
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. (Us), Дженентек, Инк. filed Critical Дженентек, Инк. (Us)
Publication of RU2010144511A publication Critical patent/RU2010144511A/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91097—Hexosyltransferases (general) (2.4.1)
    • G01N2333/91102—Hexosyltransferases (general) (2.4.1) with definite EC number (2.4.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)

Abstract

1. Способ прогнозирования чувствительности образца ткани или клеток млекопитающего к Apo2L/TRAIL, включающий в себя стадии: ! получения образца ткани или клеток млекопитающего; ! исследование образца ткани или клеток млекопитающего для выявления экспрессии GalNac-T14, где экспрессия указанной GalNac-T14 прогнозирует чувствительность указанного образца ткани или клеток к апоптоз-индуцирующей активности Apo2L/TRAIL. ! 2. Способ по п.1, в котором указанную экспрессию GalNac-T14 исследуют путем выявления экспрессии мРНК GalNac-T14. ! 3. Способ по п.1, в котором указанную экспрессию GalNac-T14 исследуют с помощью иммуногистохимии. ! 4. Способ по п.1, дополнтительно включающий в себя стадию исследования экспрессии рецепторов DR4, DR5, DcR1 или DcR2 в указанном образце ткани или клеток. ! 5. Способ по п.1, в котором образец ткани или клеток содержит злокачественную ткань или злокачественные клетки. ! 6. Способ по п.5, в котором указанные злокачественные клетки представляют собой клетки или ткань рака поджелудочной железы, лимфомы, немелкоклеточного рака легких, рака толстой кишки, колоректального рака, меланомы или хондросаркомы. ! 7. Способ индукции апоптоза в образце ткани или клеток млекопитающих, включающий в себя стадии: ! получения образца ткани или клеток млекопитающего; ! исследования образца ткани или клеток для выявления экспрессии GalNac-T14, и ! после выявления экспрессии указанной GalNac-T14 воздействие на указанный образец ткани или клеток эффективным количеством Apo2L/TRAIL. ! 8. Способ по п.7, в котором указанную экспрессию GalNac-T14 исследуют путем исследования экспрессии мРНК GalNac-T14. ! 9. Способ по п.7, в котором указанную экспрессию GalNac-T14 исследуют с помощью иммуногис

Claims (24)

1. Способ прогнозирования чувствительности образца ткани или клеток млекопитающего к Apo2L/TRAIL, включающий в себя стадии:
получения образца ткани или клеток млекопитающего;
исследование образца ткани или клеток млекопитающего для выявления экспрессии GalNac-T14, где экспрессия указанной GalNac-T14 прогнозирует чувствительность указанного образца ткани или клеток к апоптоз-индуцирующей активности Apo2L/TRAIL.
2. Способ по п.1, в котором указанную экспрессию GalNac-T14 исследуют путем выявления экспрессии мРНК GalNac-T14.
3. Способ по п.1, в котором указанную экспрессию GalNac-T14 исследуют с помощью иммуногистохимии.
4. Способ по п.1, дополнтительно включающий в себя стадию исследования экспрессии рецепторов DR4, DR5, DcR1 или DcR2 в указанном образце ткани или клеток.
5. Способ по п.1, в котором образец ткани или клеток содержит злокачественную ткань или злокачественные клетки.
6. Способ по п.5, в котором указанные злокачественные клетки представляют собой клетки или ткань рака поджелудочной железы, лимфомы, немелкоклеточного рака легких, рака толстой кишки, колоректального рака, меланомы или хондросаркомы.
7. Способ индукции апоптоза в образце ткани или клеток млекопитающих, включающий в себя стадии:
получения образца ткани или клеток млекопитающего;
исследования образца ткани или клеток для выявления экспрессии GalNac-T14, и
после выявления экспрессии указанной GalNac-T14 воздействие на указанный образец ткани или клеток эффективным количеством Apo2L/TRAIL.
8. Способ по п.7, в котором указанную экспрессию GalNac-T14 исследуют путем исследования экспрессии мРНК GalNac-T14.
9. Способ по п.7, в котором указанную экспрессию GalNac-T14 исследуют с помощью иммуногистохимии.
10. Способ по п.7, дополнительно включающий стадию исследования экспрессии рецепторов DR4, DR5, DcR1 или DcR2 в указанном образце ткани или клеток.
11. Способ по п.7, в котором указанный образец ткани или клеток содержит злокачественную ткань или клетки.
12. Способ по п.11, в котором указанные злокачественные клетки представляют собой клетки или ткань рака поджелудочной железы, лимфомы, немелкоклеточного рака легких, рака толстой кишки, колоректального рака, меланомы или хондросаркомы.
13. Способ по п.7, в котором на указанные клетки воздействуют эффективным количеством полипептида Apo2L/TRAIL, содержащего аминокислоты 114-281, представленные на Фиг.1.
14. Способ лечения заболевания у млекопитающего, например, заболевания, связанного с иммунной системой, или злокачественного заболевания, включающий в себя стадии:
получения образца ткани или клеток указанного млекопитающего;
исследования образца ткани или клеток для определения экспрессии GalNac-T14, и
после определения экспрессии указанной GalNac-T14 введение указанному млекопитающему эффективного количества Apo2L/TRAIL.
15. Способ по п.14, в котором указанную экспрессию GalNac-T14 исследуют путем выявления экспрессии мРНК GalNac-T14.
16. Способ по п.14, в котором указанную экспрессию GalNac-T14 исследуют с помощью иммуногистохимии.
17. Способ по п.14, дополнительно включающий стадию исследования экспрессии рецепторов DR4, DR5, DcR1 или DcR2 в указанном образце ткани или клеток.
18. Способ по п.14, в котором указанный образец ткани или клеток содержит злокачественную ткань или злокачественные клетки.
19. Способ по п.18, в котором указанные злокачественные клетки или ткань содержат клетки или ткань рака поджелудочной железы, лимфомы, немелкоклеточного рака легких, рака толстой кишки, колоректального рака, меланомы или хондросаркомы.
20. Способ по п.14, в котором эффективное количество полипептида Apo2L/TRAIL, содержащего аминокислоты 114-281, представленные на Фиг.1, вводят указанному млекопитающему.
21. Способ по п.14, в котором указанному млекопитающему также назначают химиотерапевтическое средство (средства) или лучевую терапию.
22. Способ по п.14, в котором указанному млекопитающему также вводят цитокин, цитотоксическое средство или ингибитор роста.
23. Способ по п.7, в котором указанный полипептид Apo2L/TRAIL связан с молекулой полиэтиленгликоля.
24. Способ по п.14, в котором указанный полипептид Apo2L/TRAIL связан с молекулой полиэтиленгликоля.
RU2010144511/15A 2005-08-16 2010-10-29 АПОПТОТИЧЕСКАЯ ЧУВСТВИТЕЛЬНОСТЬ К Apo2L/TRAIL ПУТЕМ ТЕСТИРОВАНИЯ ЭКСПРЕССИИ GalNac-N14 В КЛЕТКАХ/ТКАНЯХ RU2010144511A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70867705P 2005-08-16 2005-08-16
US60/708,677 2005-08-16
US80807606P 2006-05-24 2006-05-24
US60/808,076 2006-05-24

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2008110089/15A Division RU2416097C2 (ru) 2005-08-16 2006-08-15 АПОПТОТИЧЕСКАЯ ЧУВСТВИТЕЛЬНОСТЬ К Apo2L/TRAIL ПУТЕМ ТЕСТИРОВАНИЯ ЭКСПРЕССИИ GalNac-T14 В КЛЕТКАХ/ТКАНЯХ

Publications (1)

Publication Number Publication Date
RU2010144511A true RU2010144511A (ru) 2012-05-10

Family

ID=37758302

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2008110089/15A RU2416097C2 (ru) 2005-08-16 2006-08-15 АПОПТОТИЧЕСКАЯ ЧУВСТВИТЕЛЬНОСТЬ К Apo2L/TRAIL ПУТЕМ ТЕСТИРОВАНИЯ ЭКСПРЕССИИ GalNac-T14 В КЛЕТКАХ/ТКАНЯХ
RU2008110078/15A RU2409817C2 (ru) 2005-08-16 2006-08-15 Анализы и способы применения биомаркеров
RU2010144511/15A RU2010144511A (ru) 2005-08-16 2010-10-29 АПОПТОТИЧЕСКАЯ ЧУВСТВИТЕЛЬНОСТЬ К Apo2L/TRAIL ПУТЕМ ТЕСТИРОВАНИЯ ЭКСПРЕССИИ GalNac-N14 В КЛЕТКАХ/ТКАНЯХ

Family Applications Before (2)

Application Number Title Priority Date Filing Date
RU2008110089/15A RU2416097C2 (ru) 2005-08-16 2006-08-15 АПОПТОТИЧЕСКАЯ ЧУВСТВИТЕЛЬНОСТЬ К Apo2L/TRAIL ПУТЕМ ТЕСТИРОВАНИЯ ЭКСПРЕССИИ GalNac-T14 В КЛЕТКАХ/ТКАНЯХ
RU2008110078/15A RU2409817C2 (ru) 2005-08-16 2006-08-15 Анализы и способы применения биомаркеров

Country Status (17)

Country Link
US (3) US20080182277A1 (ru)
EP (4) EP1915625B1 (ru)
JP (7) JP5183474B2 (ru)
KR (2) KR100990266B1 (ru)
CN (2) CN101287990B (ru)
AT (2) ATE533058T1 (ru)
AU (3) AU2006279578A1 (ru)
BR (2) BRPI0616005A2 (ru)
CA (2) CA2619759A1 (ru)
DK (1) DK1915626T3 (ru)
ES (2) ES2376479T3 (ru)
IL (2) IL188869A (ru)
NO (2) NO20081375L (ru)
PT (1) PT1915626E (ru)
RU (3) RU2416097C2 (ru)
WO (2) WO2007022214A2 (ru)
ZA (2) ZA200800969B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105481788A (zh) 2006-10-28 2016-04-13 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
WO2009051268A2 (en) * 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited Preventive/remedy for cancer
WO2011087778A1 (en) * 2009-12-22 2011-07-21 The Children's Hospital Of Philadelphia Automated quantitative multidimensional volumetric analysis and visualization
PL391627A1 (pl) 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
PH12013500845A1 (en) 2010-10-29 2013-06-24 Daiichi Sankyo Co Ltd Novel anti-dr5 antibody
PT2646464E (pt) 2010-12-03 2015-10-05 Adamed Sp Zoo Proteína de fusão anticancerígena
PL219845B1 (pl) 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
PL394618A1 (pl) 2011-04-19 2012-10-22 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
PL397167A1 (pl) 2011-11-28 2013-06-10 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
PL223487B1 (pl) 2011-12-28 2016-10-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
MX350425B (es) * 2012-06-28 2017-09-05 Fluoresentric Inc Dispositivo de indicador quimico.
RU2508542C1 (ru) * 2012-07-16 2014-02-27 Полина Михайловна Шварцбурд Экспресс-способ определения риска злокачественности клеток
WO2014063246A1 (en) * 2012-10-26 2014-05-01 Fluidigm Canada Inc. Sample analysis by mass cytometry
GB201505239D0 (en) * 2015-03-27 2015-05-13 Neuro Bio Ltd Antibody
US10685210B2 (en) * 2015-08-25 2020-06-16 Koninklijke Philips N.V. Tissue microarray registration and analysis
RU2619214C1 (ru) * 2015-12-28 2017-05-12 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования течения умереннодифференцированных эндометриоидных карцином тела матки T1N0M0 при размерах первичной опухоли в пределах 1 см
RU2735918C2 (ru) * 2018-06-07 2020-11-10 Общество с ограниченной ответственностью "ДЖЕЙВИС ДИАГНОСТИКС" Набор реагентов для выявления маркера эпителиальных карцином
CN109540859B (zh) * 2018-11-27 2021-02-09 上海交通大学 一种水体中抗生素的分析和含量预测方法
RU2688181C1 (ru) * 2019-01-10 2019-05-21 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") Способ прогнозирования сроков ответа на андроген-депривационную терапию у больных раком предстательной железы
CN109825579B (zh) * 2019-01-23 2020-01-14 山东大学齐鲁医院 Galnt2作为生物标志物在胶质瘤诊断和/或治疗中的应用
RU2715223C1 (ru) * 2019-12-02 2020-02-26 Общество с ограниченной ответственностью "Медбазис" Способ определения референтных значений показателей микроорганизмов, исследуемых методом хромато-масс-спектрометрии
EP4277706A1 (en) 2021-01-15 2023-11-22 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer
CN119193695B (zh) * 2024-09-23 2025-04-25 广东省农业科学院农业生物基因研究中心 Mdh2敲除系统或抑制剂在减轻t-2毒素毒性中的应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
NZ279855A (en) 1994-02-04 1998-05-27 Bio Merieux Msrv1 and msrv2 pathogenic and/or infectious agents associated with ms, nucleic acids encoding them and diagnostic and therapeutic applications
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
DK1666591T3 (da) 1995-06-29 2011-05-23 Immunex Corp Cytokin der inducerer apoptose
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
PT939804E (pt) 1996-10-25 2005-11-30 Human Genome Sciences Inc Neutroquina alfa
DE69740107D1 (de) 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
PT1012274E (pt) 1997-01-28 2007-08-14 Craig A Rosen Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02)
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20020160446A1 (en) 2000-11-14 2002-10-31 Holtzman Douglas A. Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses
US6313269B1 (en) 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
JP4330180B2 (ja) 1997-03-17 2009-09-16 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 死ドメイン含有レセプター５
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ES2284203T5 (es) 1997-04-16 2016-03-11 Amgen Inc. Proteínas de unión a osteoprotegerina y sus receptores
AU7126498A (en) 1997-04-16 1998-11-11 Millennium Pharmaceuticals, Inc. Tumor necrosis factor receptor related proteins tango-63d and tango-63e
ES2293682T5 (es) 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
IL133122A0 (en) 1997-06-18 2001-03-19 Genentech Inc Apo-2dcr polypeptides
AU8400398A (en) 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
CA2301202A1 (en) 1997-08-15 1999-02-25 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
AU8485098A (en) 1997-08-26 1999-03-16 Genentech Inc. Rtd receptor
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
US6358682B1 (en) 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
AU2338299A (en) 1998-01-26 1999-08-09 Genentech Inc. Antibodies to death receptor 4 (dr4) and uses thereof
US6252050B1 (en) 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
US6413826B2 (en) 1999-04-07 2002-07-02 Vantis Corporation Gate insulator process for nanometer MOSFETS
EP1181319B1 (en) 1999-05-28 2009-04-22 Genentech, Inc. Chimeric dr4 antibodies and uses thereof
CN101633692A (zh) 1999-06-28 2010-01-27 杰南技术公司 利用二价金属离子制备Apo-2配体的方法
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
WO2001075166A2 (en) 2000-03-31 2001-10-11 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
DE60136816D1 (de) * 2000-07-27 2009-01-15 Genentech Inc Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
FR2828327B1 (fr) 2000-10-03 2003-12-12 France Telecom Procede et dispositif de reduction d'echo
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US7064189B2 (en) 2001-05-25 2006-06-20 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US20050129616A1 (en) 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
EP1409544B1 (en) * 2001-07-03 2009-06-17 Genentech, Inc. Human dr4 antibodies and uses thereof
IL161686A0 (en) 2001-11-01 2004-09-27 Uab Research Foundation Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
ES2357225T3 (es) 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
EP1450847B1 (en) * 2001-11-13 2010-09-29 Genentech, Inc. APO2 ligand/ TRAIL formulations and uses thereof
WO2003042367A2 (en) 2001-11-14 2003-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
AU2002361784A1 (en) 2001-12-20 2003-07-09 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
CN1189481C (zh) * 2002-03-28 2005-02-16 中国科学院动物研究所 人截短型重组可溶性trail－170蛋白及其在制备肿瘤治疗药物中的应用
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US8067152B2 (en) * 2006-02-27 2011-11-29 The Fred Hutchinson Cancer Research Center Liver cancer biomarkers

Also Published As

Publication number Publication date
EP2287615A1 (en) 2011-02-23
CN101287990B (zh) 2012-07-04
JP2011250788A (ja) 2011-12-15
PT1915626E (pt) 2012-02-03
US20130072429A1 (en) 2013-03-21
CN101287990A (zh) 2008-10-15
AU2010246471A1 (en) 2010-12-16
ZA200800969B (en) 2009-08-26
EP2306200A1 (en) 2011-04-06
ZA200800974B (en) 2009-11-25
BRPI0616005A2 (pt) 2011-05-31
ES2376479T3 (es) 2012-03-14
RU2409817C2 (ru) 2011-01-20
WO2007022214A3 (en) 2007-08-23
WO2007022157A2 (en) 2007-02-22
AU2010246471B2 (en) 2011-06-23
RU2008110078A (ru) 2009-09-27
NO20081375L (no) 2008-05-16
JP2009509500A (ja) 2009-03-12
JP2017129589A (ja) 2017-07-27
IL188869A (en) 2012-10-31
ATE540318T1 (de) 2012-01-15
KR20080029000A (ko) 2008-04-02
CA2619759A1 (en) 2007-02-22
CA2619842A1 (en) 2007-02-22
KR100990273B1 (ko) 2010-10-26
US20080182277A1 (en) 2008-07-31
EP1915625A2 (en) 2008-04-30
NO20081374L (no) 2008-05-16
DK1915626T3 (da) 2012-02-13
US20090004204A1 (en) 2009-01-01
EP1915625B1 (en) 2012-01-04
WO2007022157A3 (en) 2007-08-02
HK1115638A1 (en) 2008-12-05
ES2380119T3 (es) 2012-05-08
KR100990266B1 (ko) 2010-10-26
HK1115448A1 (en) 2008-11-28
JP5183474B2 (ja) 2013-04-17
JP5186372B2 (ja) 2013-04-17
EP1915626B1 (en) 2011-11-09
JP2014237672A (ja) 2014-12-18
RU2008110089A (ru) 2009-09-27
JP2009504186A (ja) 2009-02-05
AU2010246471B9 (en) 2012-08-02
WO2007022214A2 (en) 2007-02-22
AU2006279618A1 (en) 2007-02-22
IL188869A0 (en) 2008-04-13
BRPI0615997A2 (pt) 2011-05-31
IL188874A0 (en) 2008-04-13
JP2011244824A (ja) 2011-12-08
IL188874A (en) 2012-10-31
AU2006279578A1 (en) 2007-02-22
BRPI0615997A8 (pt) 2018-05-22
ATE533058T1 (de) 2011-11-15
CN101365951B (zh) 2013-09-11
CN101365951A (zh) 2009-02-11
EP1915626A2 (en) 2008-04-30
RU2416097C2 (ru) 2011-04-10
KR20080042087A (ko) 2008-05-14
JP2014237673A (ja) 2014-12-18

Similar Documents

Publication Publication Date Title
RU2010144511A (ru) АПОПТОТИЧЕСКАЯ ЧУВСТВИТЕЛЬНОСТЬ К Apo2L/TRAIL ПУТЕМ ТЕСТИРОВАНИЯ ЭКСПРЕССИИ GalNac-N14 В КЛЕТКАХ/ТКАНЯХ
Nakatsura et al. Identification of glypican-3 as a novel tumor marker for melanoma
Wilmott et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma
Kaira et al. Fluorine-18-α-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study
Larimer et al. Granzyme B PET imaging as a predictive biomarker of immunotherapy response
Stein et al. Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response
Massarelli et al. High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer
Zhu et al. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma
Herbst et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin
JP2008509404A5 (ru)
Li et al. 68 Ga-FAPI PET imaging monitors response to combined TGF-βR inhibition and immunotherapy in metastatic colorectal cancer
RU2007108299A (ru) Анализы и способы, использующие биомаркеры
RU2010123921A (ru) Раковый маркер и терапевтическая мишень
WO2019156568A1 (en) Methods for predicting treatment outcome and/or for selecting a subject suitable for immune checkpoint therapy
Li et al. ZBTB28 inhibits breast cancer by activating IFNAR and dual blocking CD24 and CD47 to enhance macrophages phagocytosis
Chen et al. Hepatocellular carcinoma-associated protein markers investigated by MALDI-TOF MS
Feng et al. Spatial transcriptomics reveals heterogeneity of macrophages in the tumor microenvironment of granulomatous slack skin
RU2007108300A (ru) Анализы и способы с применением биомаркеров
Conti et al. Tumor and peritumoral adipose tissue crosstalk: De-differentiated adipocytes influence spread of colon carcinoma cells
ES2837155T3 (es) Uso de PD-1 y Tim-3 como medida de células CD8+ para predecir y tratar el carcinoma de células renales
JP2008509394A5 (ru)
Michel et al. Identification of the novel differentiation marker MS4A8B and its murine homolog MS4A8A in colonic epithelial cells lost during neoplastic transformation in human colon
Lee et al. [64Cu] Cu-PEG-FUD peptide for noninvasive and sensitive detection of murine pulmonary fibrosis
Wang et al. Detection of tumor immune checkpoints: from pathological analysis to functional imaging
Li et al. High glucose accelerates tumor progression by regulating MEDAG-mediated autophagy levels in breast cancer

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20161013